Fox, S. B et al.[14] showed that PHD3 expression was significantly increased after therapy with epirubicin, alone or in combination with tamoxifen, in patients with T2-4 N0-1 breast cancer; however, PHD3 expression was not relevant in treatment response and survival. The gene discussed is EGLN3; the disease is breast carcinoma.